The Wake Forest CTSI is excited to have recently released a Translational Science Benefits Model (TSBM) case study titled, “Studying Renin to Improve Sepsis Outcomes.” This initiative, led by Dr. Ashish Khanna, focuses on the renin-angiotensin-aldosterone system (RAAS) in the quest to identify biomarkers for earlier diagnosis and personalized treatment of septic shock.
The project unites multiple healthcare sites, emphasizing collaboration to drive advances in patient care. By seeking to guide future clinical guidelines, reduce disparities, and enhance outcomes for high-risk patients, this initiative exemplifies the transformative potential of translational science. The anticipated benefits extend far beyond the laboratory, promising to revolutionize the management of septic shock and improve survival rates worldwide.
Wake Forest CTSI’s commitment to innovation and impact continues to shape the future of healthcare—one discovery at a time. View the full TSBM here.
The TSBM is a framework that helps researchers measure and demonstrate the real-world benefits of their work across four domains: clinical, community, economic, and policy. It identifies 30 specific benefits and goes beyond publication counts to track broader impacts on health and society. More information about TSBM can be found here.
The project unites multiple healthcare sites, emphasizing collaboration to drive advances in patient care. By seeking to guide future clinical guidelines, reduce disparities, and enhance outcomes for high-risk patients, this initiative exemplifies the transformative potential of translational science. The anticipated benefits extend far beyond the laboratory, promising to revolutionize the management of septic shock and improve survival rates worldwide.
Wake Forest CTSI’s commitment to innovation and impact continues to shape the future of healthcare—one discovery at a time. View the full TSBM here.